DARE earnings

Company Highlights Second Positive DSMB Review of Interim Data from Ovaprene® Phase 3 Clinical Trial, DARE to PLAY™ Anticipated Dispensing Commencement and Flora Sync LF5™ Commercial Launch Summer 2026; First Product Revenue Expected in June 2026; Call Hosted During National Women's Health Week. Conference Call and Webcast Today at 4:30 p.m. ET "We are hosting our financial results and business update call from New York, in the middle of National Women's Health Week," said Sabrina Martucci Johnson, President and Chief Executive Officer of Daré Bioscience. "Daré was built on the conviction that women's health is an investment-grade category – not a niche, not a nice-to-have, not a pink ribb

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 14, 2026, to review its financial results for the quarter ended March 31, 2026 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2531472. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at ht

Company Highlights Commercial Launch of DARE to PLAY™ Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 26, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, today reported financial results for the year ended December 31, 2025, and provided a business update. "We are not a company that is just getting into women's health. We are a women's health biotech company – and we believe 2026 is the year investors wi

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real-world solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 26, 2026, to review its financial results for the year ended December 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 1717423. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website

DARE to PLAY™ Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product RevenuePositive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal ContraceptionFour Commercially Available Solutions for Women Expected Over the Next Two Years In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of DARE to RESTORE™ Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and DARE to RECLAIM™ Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Ea

SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a purpose-driven health biotech company solely focused on closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 13, 2025, to review its financial results for the quarter ended September 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 5794075. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website a

DARE to PLAY™ Sildenafil Cream on Track for Q4 2025 Launch via 503B Compounding Pathway; Positioned for Product Revenue Beginning in Q4 2025 Positive Interim DSMB Outcome for Ovaprene® Phase 3 Study Supports Continued EnrollmentMultiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting ContraceptionFour Commercially Available Solutions for Women on the Horizon In addition to DARE to PLAY™ Sildenafil Cream, Commercialization of Vaginal Probiotics in the Consumer Health Market Targeted to follow DARE to PLAY Sildenafil Cream availability and Proprietary Monthly Hormone Therapy via 503B Compounding Pathway Targeted for Late 2026Creates Entry into the Estimated $4.5 Billi

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company with a sole focus of closing the gap in women's health between promising science and real solutions, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 14, 2025, to review its financial results for the quarter ended June 30, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 or (800) 715-9871 (toll-free). The conference ID number for the call is 2684883. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.d

Creates commercial opportunity in the estimated up to $4.5 billion compounded hormone therapy market, enabling women to access an evidence-based solutionFour on-market products will accelerate revenue generation and provide path to profitabilityDaré expects to start recording revenue in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the further expanded business strategy to commercialize multiple solutions in 2025 and 2026 2025 and 2026 Milestones Sildenafil Cream, 3.6% an investigational topical formulation of sildenafil being developed to treat female sexual arousal disorder, targeting availability via prescription as a Section 503B compounded drug t

SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 13, 2025, to review its financial results for the quarter ended March 31, 2025 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 3461324. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com.

Enables women to access a solution that they want and needCreates an opportunity to accelerate revenue generation from this proprietary formulation Daré expects to start recording revenue and cash flow in the 4th quarter of this year Conference call today at 4:30 p.m. ET to discuss the expanded business strategy to integrate 503B compounding as part of a dual-path approach to bring select Daré proprietary formulations to market as soon as practicable SAN DIEGO, March 31, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a biopharmaceutical company driven by a mission to challenge the status quo, making women's health a priority, today reported financial results for the year

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll-free). The conference ID number for the call is 9767621. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximate

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the number of clinical sites to accelerate the development timeline Sildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder - continued operational progress toward a planned Phase 3 study, including constructive discussions with FDA; Phase 3 design, development, and collaboration strategy updates

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Thursday, November 14, 2024, and prior to the conference call and webcast. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 6400145. The live webcast can be accessed under

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder continued operational progress toward a planned Phase 3 study; additional FDA feedback forthcoming; Phase 3 design, development, and collaboration strategy updates SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today reporte

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, August 12, 2024, to review its financial results for the quarter ended June 30, 2024 and to provide a company update. The company will release its financial results after the close of market on Monday, August 12, 2024, and prior to the conference call and webcast. To access the conference call via phone, dial (646) 307-1952 (U.S.) or (888) 672-2415 (international). The conference ID number for the call is 6756565. The live webcast can be accessed under "Presentation

Development Program Highlights and Anticipated 2024 Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate pivotal Phase 3 contraceptive efficacy study recruiting across the United StatesSildenafil Cream, 3.6% topical formulation of sildenafil being developed to treat female sexual arousal disorder successful completion of end-of-Phase 2 meeting with FDA; forthcoming additional FDA feedback; Phase 3 design, development, and collaboration strategy updates SAN DIEGO, May 14, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in innovation for the health and wellbeing of women, today reported financial results for the quarter ended March 31, 2024

SAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, May 14, 2024, to review its financial results for the quarter ended March 31, 2024 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (toll free). The conference ID number for the call is 5582540. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes prior t

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 28, 2024, to review its financial results for the year ended December 31, 2023 and to provide a company update. To access the conference call via phone, dial (646) 307-1963 (U.S.) or (800) 715-9871 (international). The conference ID number for the call is 7156675. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minut

Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of $1.8 million triggered by achievement of first commercial milestone under license agreement with OrganonOvaprene®: commencement of pivotal Phase 3 contraceptive efficacy studySildenafil Cream, 3.6%: end-of-Phase 2 meeting with FDADARE-PDM1: Phase 1 clinical study topline data SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2023 and provided a company update. "We are pleased with the incredible progress we have made since the beginning o

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 9, 2023, to review its financial results for the quarter ended September 30, 2023 and to provide a company update. To access the conference call via phone, dial (888) 596-4144 (U.S.) or (646) 968-2525 (international). The conference ID number for the call is 2750536. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com. Please log in approximately 5-10 m

Conference Call and Webcast Today at 4:30 p.m. ET Second Half 2023 Anticipated Milestones (target indication(s)): XACIATO™ First Commercial SaleOvaprene® (hormone-free monthly contraception) – Pivotal Phase 3 Contraceptive Efficacy Study – Patient Enrollment to Begin 4Q2023Sildenafil Cream, 3.6% (female sexual arousal disorder and female sexual interest/arousal disorder) - preparations for end-of-Phase 2 meeting with FDADARE-PDM1 (primary dysmenorrhea) – Phase 1 Clinical Study Topline DataMenopause programs: IND related activities for DARE-HRT1 (vasomotor symptoms of menopause) and DARE-VVA1 (vulvovaginal atrophy, a common condition in postmenopausal women, including those whose menopause

SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 10, 2023, to review its financial results for the quarter ended June 30, 2023 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 8451277. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes

Conference Call and Webcast Today at 4:30 p.m. ET 2023 Anticipated Milestones: Sildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Clinical Study Topline DataXACIATO™ First Commercial SaleOvaprene Pivotal Contraceptive Efficacy Study InitiationDARE-PDM1 Phase 1 Clinical Study Topline DataActivities to support IND Submission and Clinical Study Initiation for DARE-VVA1 (Phase 2) and DARE-HRT1 (Phase 3) SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended March 31, 2023 and provided a company update. "Our focused efforts to deliver differ

SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 11, 2023, to review its financial results for the quarter ended March 31, 2023 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 7046999. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes pr

Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize XACIATOTMOvaprene® IDE Approval for Pivotal Contraceptive Efficacy StudyPositive Phase 1/2 Data for both DARE-HRT1 and DARE-VVA1Three Additional Portfolio Programs (DARE-PDM1, DARE-GML and grant-funded DARE-LBT) 2023 Anticipated Milestones: XACIATO™ First Commercial SaleSildenafil Cream, 3.6% for Female Sexual Arousal Disorder Phase 2b Topline DataOvaprene Pivotal Contraceptive Efficacy Study InitiatonDARE-PDM1 Phase 1 Study Topline DataIND and Clinical Study Initiation Activities for DARE-VVA1 and DARE-HRT1 SAN DIEGO, March 30, 2023 (GLOBE NEWSW

SAN DIEGO, March 23, 2023 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year ended December 31, 2022 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S. & Canada) or (646) 307-1963 (international). The conference ID number for the call is 7242530. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-

September 30, 2022: $40.4 million in cash and cash equivalentsOvaprene®: IDE approval from FDA for pivotal Phase 3 study; additional study design considerations being reviewed and implemented to further position the study as the single pivotal study for marketing approvalDARE-HRT1: Positive topline efficacy data from Phase 1/2 clinical studySildenafil Cream, 3.6%: Completion of subject screening for Phase 2b RESPOND clinical study Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2022 and provided a c

SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 10, 2022, to review its financial results for the quarter ended September 30, 2022 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 8044477. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10

June 30, 2022: $32.1 million in cash and cash equivalentsJuly 2022: approximately $18.0 million in cash received subsequent to quarter-end: $10.0 million upfront license fee under global license agreement with Organon to commercialize XACIATOTM (clindamycin phosphate) vaginal gel, 2%, and$7.96 million under existing $48.9 million grant to fund DARE-LARC1 4Q-2022: expected U.S. commercial launch of XACIATO Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended June 30, 2022 and provided a company update. "In the secon

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Tuesday, August 9, 2022, to review its financial results for the quarter ended June 30, 2022 and to provide a Company update. To access the conference call via phone, dial (800) 715-9871 (U.S.) or (646) 307-1963 (international). The conference ID number for the call is 3817141. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes

$39.3 million in cash and cash equivalents at March 31, 2022Announced initiation of DARE-HRT1 Phase 1/2 clinical study in April 2022Organon exclusive global license agreement for XACIATO™ (clindamycin phosphate vaginal gel, 2%): Expected to close in 2Q-2022$10 million cash payment to Daré expected in 2Q-2022U.S. commercial launch expected in 4Q-2022 Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended March 31, 2022 and provided a company update. "Our global license agreement with Organon to commercialize XACIATO, an

SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, May 12, 2022, to review its financial results for the quarter ended March 31, 2022 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 7961884. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes

Entered into an exclusive global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%) that includes a $10 million upfront cash payment once effective U.S. commercial launch of XACIATO expected in 4Q-2022 Initiated communication with the FDA to support a full IDE review for Ovaprene with plans to start the pivotal Phase 3 clinical study in 2022 $51.7 million in cash and cash equivalents at December 31, 2021 Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the year ended December 31, 20

SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 31, 2022, to review its financial results for the year ended December 31, 2021 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 1185595. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minu

Prescribing information supports positioning of XACIATO as a first line option for the treatment of bacterial vaginosisThis marks the first FDA-approved product in Daré's portfolio of potential first in category development candidates Strategic partnering discussions ongoing; Conference call will be scheduled once a definitive partnership agreement for commercialization of XACIATO in the U.S. is finalized and executed; U.S. commercial launch expected 2022 SAN DIEGO, Dec. 07, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that the U.S. Food and Drug Administration (FDA) approved XACIATO [zah-she-AH-toe] (clindamycin phos

Significant progress on several key clinical and corporate initiatives with the portfolio during the third quarter, including DARE-BV1 NDA acceptance and Ovaprene NIH CRADA for the pivotal Phase 3 Actively advancing clinical development and strategic partnerships to maximize value of pipeline candidates Conference Call and Webcast Today at 4:30 p.m. ET SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended September 30, 2021 and provided a company update. "We've continued to make significant progress on several key clinical and strategic corporate initiatives with ou

SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Wednesday, November 10, 2021, to review its financial results for the quarter ended September 30, 2021 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 8459303. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10

SAN DIEGO, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today reported financial results for the quarter ended June 30, 2021 and provided a company update. "This has been, and continues to be, an incredibly productive year for Daré," said Sabrina Martucci Johnson, President and CEO of Daré Bioscience. "Consistent with our guidance, we submitted our New Drug Application for DARE-BV1, a potential new first-line treatment for bacterial vaginosis, to the FDA in June. Our NDA was accepted for filing and received Priority Review with a PDUFA target date of December 7, 2021. This year we also commenced the Phase 2b RESPOND study of

SAN DIEGO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, August 12, 2021, to review its financial results for the quarter ended June 30, 2021 and to provide a Company update. To access the conference call via phone, dial (844) 831-3031 (U.S.) or (443) 637-1284 (international). The conference ID number for the call is 5286254. The live webcast can be accessed under "Presentations, Events & Webcasts" in the Investors section of the Company's website at http://ir.darebioscience.com. Please log in approximately 5-10 minutes